A Phase 1/2 interventional study of Linvoseltamab in Relapsed/Refractory Systemic Light Chain Amyloidosis, sponsored by Regeneron Pharmaceuticals. Recruiting at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is researching an experimental drug called linvoseltamab ("study drug").
This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again.
The study consists of 2 phases (Phase 1 and Phase 2):
The study is looking at several other research questions, including:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Escalation: Non-Randomized
Drug: Linvoseltamab
Dose Escalation: Non-Randomized
Drug: Linvoseltamab
Dose Expansion: Participants will be randomized in a 1:1 ratio
Drug: Linvoseltamab
Dose Expansion: Participants will be randomized in a 1:1 ratio
Drug: Linvoseltamab
anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
Also known as: REGN5458, Lynozyfic™
Incidence of dose-limiting toxicity (DLTs)
Phase 1
Time frame: Up to 28 Days
Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)
Phase 2
Time frame: Up to 3 years
Achievement of hematologic CR, as determined by the IRC
Phase 1
Time frame: Up to 3 years
Achievement of hematologic very good partial response (VGPR) or better response (CR + VGPR), as determined by the IRC
Time frame: Up to 3 years
Achievement of overall hematologic response (PR or better), as determined by the IRC
Time frame: Up to 3 years
Time to initial hematologic response
Time frame: Up to 3 years
Time to best hematologic response
Time frame: Up to 3 years
Duration of hematologic response (ie, best response, VGPR or better, overall response), as determined by the IRC
Time frame: Up to 7 years
Hematologic progression-free survival (PFS)
Time frame: Up to 7 years
Incidence of death
Time frame: Up to 7 years
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: Up to 39 months
Severity of TEAEs
Time frame: Up to 39 months
Incidence of serious adverse events (SAEs)
Time frame: Up to 39 months
Severity of SAEs
Time frame: Up to 39 months
Incidence of adverse events of special interest (AESIs)
Time frame: Up to 39 months
Severity of AESIs
Time frame: Up to 39 months
Achievement of overall hematologic response (PR or better), as determined by the IRC in dose regimen 1 vs 2
Phase 2
Time frame: Up to 39 months
Incidence of TEAEs in dose regimen 1 vs 2
Phase 2
Time frame: Up to 39 months
Severity of TEAEs in dose regimen 1 vs 2
Phase 2
Time frame: Up to 39 months
Incidence of SAEs in dose regimen 1 vs 2
Phase 2
Time frame: Up to 39 months
Severity of SAEs in dose regimen 1 vs 2
Phase 2
Time frame: Up to 39 months
Incidence of AESIs in dose regimen 1 vs 2
Phase 2
Time frame: Up to 39 months
Severity of AESIs in dose regimen 1 vs 2
Phase 2
Time frame: Up to 39 months
Time from treatment initiation to hematologic disease progression as determined by the IRC
Time frame: Up to 7 years
Time from treatment initiation to cardiac deterioration, as determined by the IRC
Time frame: Up to 7 years
Time from treatment initiation to kidney deterioration as determined by the IRC
Time frame: Up to 7 years
Time from treatment initiation to death as determined by the IRC
Time frame: Up to 7 years
Time from initiation of treatment to date of death from any cause
Time frame: Up to 7 years
Achievement of renal response in participants with renal involvement at baseline, as determined by IRC
Time frame: Up to 7 years
Achievement of cardiac response in participants with cardiac involvement at baseline, as determined by IRC
Time frame: Up to 7 years
Time to first renal response in participants with renal involvement at baseline
Time frame: Up to 7 years
Time to first cardiac response in participants with cardiac involvement at baseline
Time frame: Up to 7 years
Linvoseltamab concentration in serum over time
Time frame: Up to 39 months
Incidence of anti-drug antibodies (ADAs) to linvoseltamab over time
Time frame: Up to 39 months
Titers of ADAs to linvoseltamab over time
Time frame: Up to 39 months
Not enrolling at this site — choose another above.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Aug 2028, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linvoseltamab